Compare Heron Therapeutics Inc (HRTX) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs PAGSEG Inc — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while PAGSEG Inc trades at $9.37 (market cap $2.60B). The key difference: PAGSEG Inc is far larger — about 28.4× Heron Therapeutics Inc's market cap, and PAGSEG Inc pays a 11.19% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | PAGS | |
|---|---|---|
Market Cap | $91.46M | $2.60B |
Sector | Health | Technology |
52-Week High | $1.96 | $12.00 |
52-Week Low | $0.39 | $7.75 |
Enterprise Value | $189.36M | $10.23B |
Dividend Yield | — | 11.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
PAGS trades at $9.29, up 2.77% today, with bearish technical signals but strong fundamentals including a P/E of 6.4 and net income margin of 10.4%. Recent earnings showed a Q1 2026 miss at $0.39 EPS versus $0.40 expected, while Q4 2025 beat expectations. The company maintains robust cash flow from operations of $7.56B in 2025 and declared a $0.26 dividend for H1 2026, payable June 1, 2026.
The stock presents a value opportunity with low valuation multiples and solid profitability, though technical weakness and mixed earnings create near-term uncertainty. Risks include Brazilian macroeconomic sensitivity and competitive pressures, but analyst consensus is strongly bullish with 62.5% buy ratings, suggesting upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
